Akum

Akums Drugs & Pharmaceuticals Ltd. operates as a prominent Indian pharmaceutical Contract Development and Manufacturing Organization (CDMO), catering to both domestic and international pharmaceutical companies. Established on April 19, 2004, by brothers Sanjeev and Sandeep Jain, the company emerged from their early experiences in the pharmaceutical wholesale business, where they identified a significant gap between the demand and supply of medicines. This realization prompted them to venture into contract manufacturing, establishing their first plant in Haridwar, Uttarakhand. The founders' journey began in a small wholesale shop in Delhi, a venture they started after completing their 12th-grade education due to challenging financial circumstances. Today, Sanjeev Jain manages business development, sales, and marketing, while Sandeep Jain oversees operations across the company's extensive manufacturing facilities.

The core of Akums' business model is providing end-to-end solutions for its clients, which includes research and development, formulation, manufacturing, quality assurance, and regulatory compliance. The company generates revenue by manufacturing a wide array of pharmaceutical products for other companies under their brand names. Its client roster includes 26 of the top 30 pharmaceutical companies in India. The business is structured into three main segments: CDMO, which is the flagship business contributing approximately 79% of the turnover; Branded and Generic Formulations, which are marketed in India and over 65 countries; and Active Pharmaceutical Ingredients (APIs).

Akums offers a comprehensive portfolio of products and services. The company manufactures over 4,100 commercialized formulations in more than 60 dosage forms, such as tablets, capsules, soft gels, liquid orals, injectables, and hormonal preparations. They also produce nutraceuticals, cosmetics, and ayurvedic products. Manufacturing operations are spread across more than a dozen state-of-the-art facilities that adhere to global regulatory standards like WHO-GMP and are equipped to handle large-scale production. A significant milestone was the company's public listing on August 6, 2024, reflecting strong investor confidence. The company has also made strides in global expansion, receiving its first European dossier approval and signing a major long-term contract to supply products to Europe.

Keywords: Contract Development and Manufacturing Organization, CDMO, pharmaceutical manufacturing, Sanjeev Jain, Sandeep Jain, pharmaceutical formulations, Active Pharmaceutical Ingredients, API, nutraceutical manufacturing, dermatological products, generic drugs, branded pharmaceuticals, Indian pharmaceutical industry, drug development, regulatory compliance, quality assurance, pharmaceutical R&D, dosage forms, oral solids, liquid orals, injectables, global pharmaceutical supply, Haridwar manufacturing, pharmaceutical exports